These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 39405927)
1. RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation. Zhang Z; Liu B; Mei L; Chen R; Zhou H; Li Z Int Immunopharmacol; 2024 Dec; 143(Pt 1):113312. PubMed ID: 39405927 [TBL] [Abstract][Full Text] [Related]
2. SPP1 could be an immunological and prognostic biomarker: From pan-cancer comprehensive analysis to osteosarcoma validation. Zhang Z; Liu B; Lin Z; Mei L; Chen R; Li Z FASEB J; 2024 Jul; 38(14):e23783. PubMed ID: 39037571 [TBL] [Abstract][Full Text] [Related]
3. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048 [TBL] [Abstract][Full Text] [Related]
4. DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma. Zhu D; Feng H; Zhang Z; Li J; Li Y; Hou T Cancer Med; 2024 Aug; 13(15):e70043. PubMed ID: 39087856 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Yang H; Zhao L; Zhang Y; Li FF Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887 [TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy. Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X Front Genet; 2022; 13():938510. PubMed ID: 36171879 [No Abstract] [Full Text] [Related]
8. Develop a Novel Signature to Predict the Survival and Affect the Immune Microenvironment of Osteosarcoma Patients: Anoikis-Related Genes. Yang M; Su Y; Xu K; Zheng H; Cai Y; Wen P; Yang Z; Liu L; Xu P J Immunol Res; 2024; 2024():6595252. PubMed ID: 39431237 [TBL] [Abstract][Full Text] [Related]
9. Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma. Li Q; Huang X; Zhao Y Cancer Biother Radiopharm; 2024 Sep; 39(7):502-516. PubMed ID: 37889617 [No Abstract] [Full Text] [Related]
10. UBR1 is a prognostic biomarker and therapeutic target associated with immune cell infiltration in gastric cancer. Yuan W; Han J; Chen C; Qiu Y; Xu Y; Huang Y; Chen Z; Xu A; Sun M Aging (Albany NY); 2024 Aug; 16(16):12029-12049. PubMed ID: 39181686 [TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker. Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933 [TBL] [Abstract][Full Text] [Related]
13. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J Front Immunol; 2021; 12():812713. PubMed ID: 35069601 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment. Wu Z; Pan T; Li W; Zhang YH; Guo SH; Liu Y; Zhang L; Wang ZY Clin Transl Oncol; 2024 Oct; 26(10):2701-2717. PubMed ID: 38642258 [TBL] [Abstract][Full Text] [Related]
15. Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation. Huang S; Tan C; Zheng J; Huang Z; Li Z; Lv Z; Chen W; Chen M; Yuan X; Chen C; Yan Q Immunobiology; 2024 Sep; 229(5):152836. PubMed ID: 39018675 [TBL] [Abstract][Full Text] [Related]
16. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immunological role of PDCD1 gene in pan-cancer. Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926 [TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy. Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107 [TBL] [Abstract][Full Text] [Related]
19. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
20. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J Front Immunol; 2021; 12():788431. PubMed ID: 34970268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]